Notably, Poloppin sensitivity persists in cancer cells resistant to an ATP-competitive PLK1 inhibitor, and Poloppin sensitizes mutant KRAS-expressing cells to clinically used inhibitors of the MET tyrosine kinase, opening opportunities for combination therapy. The gene discussed is PLK1; the disease is cancer.